Creo Medical Group announces Kevin Crofton and Brent Boucher to join its Board as Independent Directors

– UK, Chepstow –  Creo Medical Group plc (LON: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, today announced the appointment of Kevin Crofton and Brent Boucher to its Board as Independent Non-Executive Directors effective from 1 July 2024, with Kevin succeeding Charles Spicer as Chair.

“We are delighted to appoint Non-Executive Directors of the calibre of Kevin and Brent. They are stalwart international executives, bringing with them deep industry knowledge as well as proven strategic capabilities and senior commercial execution experience. It has been a pleasure to get to know both Kevin and Brent over the last few months as we have worked through the selection process and begun to immerse them into the team and the business. I look forward to working with them on the next stage of Creo’s journey.” said CEO, Craig Gulliford.

About Kevin Crofton

Kevin Crofton is an accomplished business leader with over three decades of extensive international experience in the technology industry. He has a successful track record of driving innovation and generating profitable growth. Most recently, Kevin was the CEO of Comet Holdings AG, a Swiss-listed technology company, where he delivered significant shareholder value by driving greater customer engagement. Before this, he was CEO of SPTS Technologies where he led the PE-backed management buyout and exit of the company to Orbotech, Inc., joining the team that subsequently sold the group to KLA-Tencor Corporation for $3.4bn. Kevin has also acted as Chairman of SEMI International and the UK Compound Semiconductor Applications Catapult.

About Brent Boucher

Brent Boucher brings extensive experience in the commercialization of novel medical devices and has a record of success in growing and transforming businesses across a range of medical device specialties, including technologies, oncology interventions, surgical solutions, and respiratory care. Brent is recognized as a business leader of multiple innovative growth businesses focused on commercial optimization, new product, technology, and procedural introductions, global market entry, and strategic M&A. Throughout his career in the USA, Brent has held several executive positions in large multinational Medtech companies, including Covidien (acquired by Medtronic), AngioDynamics and Nuvasive, working to successfully deliver revenue growth and shareholder value.

About Creo Medical

Creo Medical is a medical device company focused on the development and commercialization of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialization of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimize surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimized to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision, and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency energy for precise localized cutting and focused high-frequency microwave energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group’s range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate, and controlled clinical solutions. The Directors believe the Company’s technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive,e and more cost-efficient option for procedures.


- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.